TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause

Retrospective database analysis using TriNetX database to describe HES patient characteristics, journey, and disease burden.

Inclusion criteria

• Diagnosis record of HES (ICD-10-CM D72.11) anytime during 01 October 2020 to 30 June 2023
• At least 12 months of patient insurance record prior to first HES record.

Exclusion criteria

• Any mutation in PDGFRA, PDGFRB or FGFR1 genes (to exclude clonal HES).
• History of BCR-ABL tyrosine kinase inhibitor use: imatinib, dasatinib, nolitinib, bosutinib, ponatinib, asciminib (to exclude clonal HES)
• History of myeloid leukemia, myeloproliferative disorder, myelodysplastic disorder, myelomonocytic leukemia, acute erythroid leukemia, acute megakaryoblastic leukaemia, acute panmyelosis with myelofibrosis, and other specified leukaemias (to exclude reactive HES)
• History of helminthiasis or use of anthelmintic medication (to exclude reactive HES)
• History of autoimmune disease (to exclude reactive HES)
• History of use of specific drugs: antiepileptics, sulfonamides, allopurinol, and immune checkpoint inhibitors (to exclude reactive HES)